Analysis of immunological status using CFSE-MLR for de-novo kidney transplant recipients who are treated with Everolimus commencing 3 months after surgery.
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 17 May 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.
- 21 May 2013 New trial record